Ponesimod
Genentech announces positive clinical results for BTK inhibitor MS treatment
Multiple sclerosis affects more than 2.9 million people globally
Johnson & Johnson files FDA application for Tremfya in psoriatic arthritis
Approximately 125 million people globally are living with some form of psoriasis
Johnson & Johnson’s TAR-200 granted FDA priority review to treat bladder cancer
An estimated 84,870 people will be diagnosed with bladder cancer in the US this year
Tiziana Life Sciences’ intranasal MS candidate shows promise in open-label study
Approximately 2.9 million people worldwide are living with the neurodegenerative disease
Johnson & Johnson’s Tremfya granted EC approval to treat ulcerative colitis in adults
More than 2.5 million people in Europe are living with the inflammatory bowel disease
Sanofi’s tolebrutinib shown to delay MS disability progression in phase 3 study
The BTK inhibitor has been granted FDA priority review to treat the neurodegenerative disease
J&J’s Stelara granted EC approval to treat Crohn’s disease in paediatric patients
Approximately 25% of cases are diagnosed during childhood or adolescence
Johnson & Johnson’s Tremfya recommended by CHMP to treat Crohn’s disease
Inflammatory bowel disease is estimated to affect nearly two million people across Europe
J&J shares overall survival results for Rybrevant/Lazcluze combination in lung cancer
The regimen was approved by the MHRA earlier this month to treat EGFR-mutated NSCLC
Sanofi’s investigational MS treatment tolebrutinib granted FDA priority review
Approximately 2.9 million people worldwide are living with the neurodegenerative disease
Johnson & Johnson to invest more than $55bn in US over next four years
The commitment marks a 25% increase to the company's US investments in the past four years
Johnson & Johnson’s Tremfya granted FDA approval to treat Crohn’s disease
An estimated three million people in the US are affected by inflammatory bowel disease